TCRR News and Press, TCR2 Therapeutics Inc. From 10/12/21

Today, we are taking our first look at TCR Therapeutics since May of this year. The company continues to advance its early-stage pipeline, but the stock took a recent tumble after some interim trial results were posted. Time to buy the dip? A full investment analysis is prese...

CAMBRIDGE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the e-poster presentation of new preclinical data at the Americ...

The following slide deck was published by TCR2 Therapeutics Inc. in conjunction with this event. For further details see: Tcr2 Therapeutics (TCRR) presents Interim Data from Ongoing Gavo-cel Phase 1/2 Clinical Trial

The following slide deck was published by TCR2 Therapeutics Inc. in conjunction with this event. For further details see: TCR2 Therapeutics (TCRR) Investor Presentation

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks touched their lowest levels in four weeks Friday as inflation fears took hold and a range of Chinese economic indicators pointed to a ...

Healthcare stocks in the S&P 500 edged past the ~0.6% loss in the broader index over the week to end ~0.2% lower, becoming the fourth best performing sector. Among stocks with more than $300M market cap and over 100K average daily volume over the past five sessions, BELLUS Health (NA...

COVID boost shots and drug development marked crucial themes in Friday's trading as a closely watched U.S. government panel met and backed a third COVID vaccine shot for certain Americans. COVID vaccine makers BioNTech (NASDAQ:BNTX), Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) all lost ground...

TCR2 Therapeutics Inc. (NASDAQ: TCRR) has announced positive interim results from its Phase 1 portion of the gavo-cel Phase ½ clinical trial for mesothelin-expressing solid tumors.  As of June 30, 2021, 17 patients have received a single gavo-cel infusion in the phas...

- Clinical activity observed in all three mesothelin-expressing tumor types treated - Gavo-cel disease control rate (DCR) 81% with tumor regression in 15 of 16 evaluable patients - Overall response rate (ORR) 31% in patients infused with gavo-cel following lymphodepletion - Mean...

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company will host a conference call and live audio we...